摘要
卵巢癌是病死率最高的妇科恶性肿瘤,易产生化疗耐药而复发死亡,5年生存率仅为40%左右。环状RNA (circRNA)是一类单链共价闭合的非编码RNA,稳定丰富存在于生物体细胞核、细胞质和体液中,成为近年来卵巢癌调控研究的热点。该文从细胞凋亡、上皮间充质转化、细胞周期、自噬和生物标志物方面系统综述了与卵巢癌调控相关的62个circRNAs,其中包括与卵巢癌顺铂和紫杉烷类化疗耐药显著相关的15个circRNAs;并从竞争性内源RNA、功能蛋白互作、翻译成多肽和蛋白质,以及信号通路方面对circRNA调控卵巢癌及其化疗耐药的分子机制进行了梳理,以期为后续circRNA调控卵巢癌及其化疗耐药的相关研究提供参考。
Ovarian cancer is a gynecological malignant tumor with the highest mortality rate.Patients with ovarian cancer are prone to relapse and death due to chemotherapy resistance,with a five-year survival rate of only about 40%.Circular RNAs(circRNAs) are single-stranded,covalently closed non-coding RNAs.They are stable and abundant in the cell nucleus,cell cytoplasm,and body fluids of organisms,and have become a hot topic in the field of ovarian cancer regulation in recent years.This review systematically summarizes 62 circRNAs associated with the regulation of ovarian cancer in terms of apoptosis,epithelial-mesenchymal transition,cell cycle,autophagy,and biomarkers,including 15 circRNAs that are significantly associated with cisplatin and taxane resistance in ovarian cancer.Additionally,the molecular mechanisms underlying the roles of circRNAs in regulating development and chemoresistance of ovarian cancer are reviewed from the perspectives of competing endogenous RNA,functional protein-protein interaction,peptide and protein synthesis,and signaling pathways,so as to provide insights for future studies on roles of circRNAs in regulating development and chemoresistance of ovarian cancer.
作者
陈小英
柯瑶
刘夏
苏宇婷
王聪
尹富强
Chen Xiao-ying;Ke Yao;Liu Xia;Su Yu-ting;Wang Cong;Yin Fu-qiang(School of Preclinical Medicine,Guangxi Medical University,Nanning,Guangxi 530021,China;Life Sciences Institute and Key Laboratory of High-Incidence-Tumor Prevention&Treatment,Guangxi Medical University,Nanning,Guangxi 530021,China;Key Laboratory of Longevity and Ageing-Related Disease of Chinese Ministry of Education,Guangxi Medical University,Nanning,Guangxi 530021,China)
出处
《中国现代医学杂志》
CAS
2024年第6期46-53,共8页
China Journal of Modern Medicine
基金
国家自然科学基金(No:81860458,No:81903644)
广西自然科学基金(No:2021GXNSFAA075002、2018GXNSFAA281227)
广西医科大学高水平创新团队及杏湖学者计划(No:24/02304001018X)
区域性高发肿瘤早期防治研究教育部重点实验室自主研究项目(No:GKE-ZZ202017、GKE-ZZ202148)。